{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T03:41:05Z","timestamp":1780371665140,"version":"3.54.1"},"reference-count":31,"publisher":"American Medical Association (AMA)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Post\u2013COVID-19 condition (PCC) contributes substantially to long-term morbidity after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Information about the effectiveness of oral antivirals in preventing PCC in outpatient populations remains limited.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To evaluate the association between early oral antiviral use and PCC risk among outpatients with COVID-19, with and without risk factors for severe disease.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n Prospective, nationwide, multicenter, registry-based cohort study conducted at 51 acute-care hospitals across Japan during the predominance of Omicron sublineages JN.1 and KP.3. Outpatients aged 12 years or older with laboratory-confirmed COVID-19, symptom onset of 5 days or less before enrollment, and no recent anti\u2013SARS-CoV-2 treatment were enrolled between February and October 2024, with follow-up through February 2025. The primary analysis population included participants with complete baseline covariates and valid day 28 and day 84 assessments.<\/jats:p>\n <\/jats:sec>\n \n Exposures<\/jats:title>\n Oral antiviral use (ensitrelvir, nirmatrelvir, or molnupiravir) at enrollment vs no antiviral use.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The primary outcome was PCC, defined as persistence of 1 or more of 5 prespecified symptoms (cough, shortness of breath, malaise, smell disorder, or taste disorder), with the same symptoms reported on both days 28 and 84. Exploratory outcomes included failure to return to usual health by day 84.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Among 7699 participants (2181 receiving antivirals: 1131 [51.9%] male; median [IQR] age, 58.0 [41-71] years; and 5518 without antivirals: 2928 [53.1%] female; median [IQR] age, 45.0 [29-57] years), most had mild COVID-19 (7599 participants [98.7%]) and received 2 or more vaccine doses (6902 participants [89.6%]). Participants receiving antivirals were older and had more comorbidities; other baseline characteristics were similar between groups. After prespecified adjustment, antiviral use was associated with a lower risk of PCC (adjusted risk ratio [aRR], 0.86; 95% CI, 0.78-0.93). Results were consistent for ensitrelvir (aRR, 0.86; 95% CI, 0.79-0.95) and molnupiravir (aRR, 0.81; 95% CI, 0.67-0.98). Failure to return to usual health by day 84 was less common among participants receiving antivirals than among participants without antivirals (9.9% vs 12.9%; aRR, 0.77; 95% CI, 0.67-0.89).<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this cohort study of outpatients with COVID-19, early oral antiviral use was associated with a lower risk of PCC. These findings suggest that early antiviral treatment may help mitigate long-term consequences of SARS-CoV-2 infection.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2026.11983","type":"journal-article","created":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T15:30:31Z","timestamp":1778859031000},"page":"e2611983","source":"Crossref","is-referenced-by-count":1,"title":["Early-Phase Oral Antiviral Use and Post\u2013COVID-19 Condition in Outpatients"],"prefix":"10.1001","volume":"9","author":[{"given":"Makoto","family":"Hibino","sequence":"first","affiliation":[{"name":"Department of Respiratory Medicine, Shonan Oiso Hospital, Kanagawa, Japan"},{"name":"Department of Respiratory Medicine, Shonan Fujisawa Tokushukai Hospital, Kanagawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayumi","family":"Shintani","sequence":"additional","affiliation":[{"name":"Department of Medical Statistics, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Murayama","sequence":"additional","affiliation":[{"name":"Surgical Department, Narita Tomisato Tokushukai Hospital, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Morikawa","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Tokyo Nishi Tokushukai Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazunari","family":"Maeda","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Shonan Fujisawa Tokushukai Hospital, Kanagawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sho","family":"Nishiguchi","sequence":"additional","affiliation":[{"name":"Department of General Internal Medicine, Shonan Kamakura General Hospital, Kanagawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiji","family":"Monma","sequence":"additional","affiliation":[{"name":"Department of Surgery, Koga General Hospital, Ibaraki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromasa","family":"Harada","sequence":"additional","affiliation":[{"name":"Department of General Medicine, Yao Tokushukai General Hospital, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsunekazu","family":"Takagi","sequence":"additional","affiliation":[{"name":"Department of Neurology, Suita Tokushukai Hospital, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Kuroyanagi","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Surgery, Kishiwada Tokushukai Hospital, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyoshi","family":"Endo","sequence":"additional","affiliation":[{"name":"Department of Surgery, Ikoma City Hospital, Nara, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Terada","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Surgery, Shonai Amarume Hospital, Yamagata, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Kinoshita","sequence":"additional","affiliation":[{"name":"Medical Affairs Department, Shionogi and Co Ltd, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Yoden","sequence":"additional","affiliation":[{"name":"Medical Affairs Department, Shionogi and Co Ltd, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shogo","family":"Miyazawa","sequence":"additional","affiliation":[{"name":"Data Science Department, Shionogi and Co Ltd, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichi","family":"Higashiue","sequence":"additional","affiliation":[{"name":"Tokushukai Medical Corporation, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,5,15]]},"reference":[{"issue":"1","key":"zoi260365r1","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s12982-024-00364-x","article-title":"Key insights into recent advances and challenges in COVID-19 management.","volume":"22","author":"Monika","year":"2025","journal-title":"Discov Public Health"},{"issue":"4","key":"zoi260365r2","doi-asserted-by":"publisher","first-page":"424","DOI":"10.3390\/vaccines13040424","article-title":"Beyond the pandemic era: recent advances and efficacy of SARS-CoV-2 vaccines against emerging variants of concern.","volume":"13","author":"Saha","year":"2025","journal-title":"Vaccines (Basel)"},{"issue":"1","key":"zoi260365r3","doi-asserted-by":"publisher","first-page":"4249","DOI":"10.1038\/s41467-025-59012-w","article-title":"The risk of Long Covid symptoms: a systematic review and meta-analysis of controlled studies.","volume":"16","author":"O\u2019Mahoney","year":"2025","journal-title":"Nat Commun"},{"issue":"9","key":"zoi260365r4","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaf533","article-title":"Global prevalence of long COVID, its subtypes, and risk factors: an updated systematic review and meta-analysis.","volume":"12","author":"Hou","year":"2025","journal-title":"Open Forum Infect Dis"},{"issue":"18","key":"zoi260365r5","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1056\/NEJMsb2408466","article-title":"National Academies of Sciences Engineering and Medicine Committee on examining the working definition for long covid. Long COVID defined.","volume":"391","author":"Ely","year":"2024","journal-title":"N Engl J Med"},{"issue":"4","key":"zoi260365r6","doi-asserted-by":"publisher","first-page":"e102","DOI":"10.1016\/S1473-3099(21)00703-9","article-title":"A clinical case definition of post-COVID-19 condition by a Delphi consensus.","volume":"22","author":"Soriano","year":"2022","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"zoi260365r7","doi-asserted-by":"publisher","first-page":"156","DOI":"10.23736\/S0026-4806.25.09539-4","article-title":"Long COVID: emerging pathophysiological mechanisms.","volume":"116","author":"Mueller","year":"2025","journal-title":"Minerva Med"},{"issue":"20","key":"zoi260365r8","doi-asserted-by":"publisher","first-page":"5500","DOI":"10.1016\/j.cell.2024.07.054","article-title":"Mechanisms of long COVID and the path toward therapeutics.","volume":"187","author":"Peluso","year":"2024","journal-title":"Cell"},{"issue":"23","key":"zoi260365r9","doi-asserted-by":"publisher","first-page":"7375","DOI":"10.3390\/jcm12237375","article-title":"Effectiveness of antiviral therapy on long COVID: a systematic review and meta-analysis.","volume":"12","author":"Choi","year":"2023","journal-title":"J Clin Med"},{"key":"zoi260365r10","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2024.105958","article-title":"Prevention of post COVID-19 condition by early treatment with ensitrelvir in the phase 3 SCORPIO-SR trial.","volume":"229","author":"Yotsuyanagi","year":"2024","journal-title":"Antiviral Res"},{"issue":"6","key":"zoi260365r11","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1001\/jamainternmed.2023.0743","article-title":"Association of treatment with nirmatrelvir and the risk of post-COVID-19 condition.","volume":"183","author":"Xie","year":"2023","journal-title":"JAMA Intern Med"},{"issue":"10","key":"zoi260365r12","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1016\/S1473-3099(24)00217-2","article-title":"Association of nirmatrelvir-ritonavir with post-acute sequelae and mortality in patients admitted to hospital with COVID-19: a retrospective cohort study.","volume":"24","author":"Wang","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"zoi260365r13","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2022-074572","article-title":"Molnupiravir and risk of post-acute sequelae of covid-19: cohort study.","volume":"381","author":"Xie","year":"2023","journal-title":"BMJ"},{"issue":"6","key":"zoi260365r17","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1056\/NEJMoa2116044","article-title":"Molnupiravir for oral treatment of COVID-19 in nonhospitalized patients.","volume":"386","author":"Jayk Bernal","year":"2022","journal-title":"N Engl J Med"},{"issue":"2","key":"zoi260365r20","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.54991","article-title":"Efficacy and safety of 5-day oral ensitrelvir for patients with mild to moderate COVID-19: the SCORPIO-SR randomized clinical trial.","volume":"7","author":"Yotsuyanagi","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"8","key":"zoi260365r22","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1007\/s40121-024-01010-4","article-title":"Real-world effectiveness of ensitrelvir in reducing severe outcomes in outpatients at high risk for COVID-19.","volume":"13","author":"Takazono","year":"2024","journal-title":"Infect Dis Ther"},{"key":"zoi260365r25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2024.107265","article-title":"Impact of early antiviral therapy on SARS-CoV-2 clearance time in high-risk COVID-19 subjects: a propensity score matching study.","volume":"149","author":"Colaneri","year":"2024","journal-title":"Int J Infect Dis"},{"issue":"9","key":"zoi260365r26","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1001\/jamainternmed.2024.2007","article-title":"Nirmatrelvir-Ritonavir and symptoms in adults with postacute sequelae of SARS-CoV-2 infection: the STOP-PASC randomized clinical trial.","volume":"184","author":"Geng","year":"2024","journal-title":"JAMA Intern Med"},{"issue":"8","key":"zoi260365r27","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1016\/S1473-3099(25)00073-8","article-title":"Nirmatrelvir-ritonavir versus placebo-ritonavir in individuals with long COVID in the USA (PAX LC): a double-blind, randomised, placebo-controlled, phase 2, decentralised trial.","volume":"25","author":"Sawano","year":"2025","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"zoi260365r28","doi-asserted-by":"publisher","first-page":"19049","DOI":"10.1038\/s41598-024-69772-y","article-title":"Patients recovering from COVID-19 who presented with anosmia during their acute episode have behavioral, functional, and structural brain alterations.","volume":"14","author":"Kausel","year":"2024","journal-title":"Sci Rep"},{"issue":"2","key":"zoi260365r29","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1002\/acn3.51710","article-title":"Structural brain changes in post-acute COVID-19 patients with persistent olfactory dysfunction.","volume":"10","author":"Campabadal","year":"2023","journal-title":"Ann Clin Transl Neurol"},{"issue":"1","key":"zoi260365r30","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3390\/diseases13010004","article-title":"Persistent post\u2013COVID-19 olfactory dysfunction and its association with autonomic nervous system function: a case-control study.","volume":"13","author":"Ayoub","year":"2024","journal-title":"Diseases"},{"issue":"1","key":"zoi260365r31","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/s41392-023-01451-2","article-title":"Immunosenescence: molecular mechanisms and diseases.","volume":"8","author":"Liu","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"zoi260365r14","unstructured":"Shionogi and Co. Ltd. XOCOVA pack: patient medicine guide for ensitrelvir. Shionogi and Co. Ltd. 2025. Accessed September 23, 2025. https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/ResultDataSetPDF\/340018_6250052F1023_2_11"},{"key":"zoi260365r15","unstructured":"Merck Sharp and Dohme LLC. LAGEVRIO (molnupiravir) for oral use. Fact sheet for healthcare providers: emergency use authorization. Merck Sharp and Dohme LLC. 2024. Accessed July 5, 2025. https:\/\/www.merck.com\/eua\/molnupiravir-hcp-fact-sheet.pdf"},{"key":"zoi260365r16","unstructured":"Pfizer Inc. PAXLOVID pack: patient medicine guide for ritonavir-boosted nirmatrelvir. 2025. Accessed July 24, 2025. https:\/\/www.info.pmda.go.jp\/downfiles\/ph\/GUI\/672212_62501B5X1020_1_00G.pdf"},{"key":"zoi260365r18","unstructured":"Pfizer Inc. PAXLOVID (ritonavir-boosted nirmatrelvir) for oral use. Pfizer Inc. 2025. Accessed July 5, 2025. https:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=19599"},{"key":"zoi260365r19","unstructured":"MSD K. K. LAGEVRIO (molnupiravir) capsules. MSD K. K. 2025. Accessed July 29, 2025. https:\/\/www.msdconnect.jp\/wp-content\/uploads\/sites\/5\/2025\/10\/pi_lagevrio_or.pdf"},{"key":"zoi260365r21","unstructured":"Japan Ministry of Health, Labour and Welfare. COVID-19 clinical management guide, version 10.1. Accessed September 12, 2025. https:\/\/www.mhlw.go.jp\/content\/001248424.pdf"},{"key":"zoi260365r23","unstructured":"covSPECTRUM Japan. All lineages. Accessed August 21, 2025. https:\/\/cov-spectrum.org\/explore\/Japan\/AllSamples\/from%3D2024-02-01%26to%3D2025-01-31\/variants?&"},{"key":"zoi260365r24","unstructured":"US Centers for Disease Control and Prevention. Underlying conditions and the higher risk for severe COVID-19. Accessed December 5, 2025. https:\/\/archive.cdc.gov\/www_cdc_gov\/coronavirus\/2019-ncov\/hcp\/clinical-care\/underlyingconditions.html"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2849100\/hibino_2026_oi_260365_1778259674.01428.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T15:30:36Z","timestamp":1778859036000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2849100"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,15]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2026.11983","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,15]]}}}